Faisal G. Sukhtian Takes Helm at Outlook Therapeutics as Chairman

Outlook Therapeutics, a biopharmaceutical company specializing in the development and commercialization of ophthalmologic treatments, has appointed Faisal G. Sukhtian as Chairman of the Board of Directors. This strategic move comes as the company prepares to launch LYTENAVA, a new treatment for wet age-related macular degeneration (wet AMD), in the European Union and the United Kingdom. The appointment signifies a pivotal moment for Outlook Therapeutics, which has transitioned from a preclinical biotech to a company on the brink of bringing its inaugural product to market, both in Europe and potentially the United States, pending FDA approval. Faisal G. Sukhtian, who has been with the board since 2017, brings a wealth of experience from his position as Executive Director at GMS Holdings. He has been involved in the biopharma and life sciences sector, with extensive experience in operations, strategy development, and M&A. Under Sukhtian's leadership, the company aims to advance its market reach, leveraging his expertise and the financial backing of GMS Ventures and Investments. The former Chairman, Randy Thurman, will continue to serve as Lead Independent Director, continuing his journey with Outlook Therapeutics and focusing on the worldwide approval and launch of LYTENAVA. His leadership has been instrumental in guiding the company towards this critical phase. Outlook Therapeutics plans to initiate the commercial launch of LYTENAVA in the first half of 2025 in the EU and UK while working towards regulatory approval in the United States. The company's commitment to addressing retina diseases highlights the therapeutic potential of LYTENAVA as a landmark treatment, with significant implications for patient care in ophthalmology. The appointment of Faisal G. Sukhtian is a testament to a robust growth strategy as the company navigates complex regulatory landscapes and aims for global product deployment.